Literature DB >> 26187335

[Immunological tumor therapy].

K Dietrich1, M Theobald.   

Abstract

Tumor cells could fundamentally be recognized and eliminated by the immune system but malignant cells are able to escape the immune surveillance system. The idea of immunotherapy of cancer is to activate, modulate and amplify the host immune response or to genetically equip the immune repertoire of patients with anti-tumor specificities and effectors. In recent years, a variety of promising immunotherapy strategies have been developed, such as bispecific, multispecific and immunoregulatory antibodies, gene-modified T lymphocytes and tumor vaccines. Some drugs have already been approved and others are available for patients in clinical trials. This article presents the current anti-tumor immune strategies and their molecular basis. Even though further research is needed in some areas, such as the establishment of biomarkers for targeted therapy, duration of therapeutic activity and compatibility of combined strategies, cancer immunotherapy is likely to be a key component in oncological treatment concepts in the very near future.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26187335     DOI: 10.1007/s00108-015-3744-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  31 in total

1.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

2.  Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.

Authors:  Steven A Rosenberg; James C Yang; Richard M Sherry; Udai S Kammula; Marybeth S Hughes; Giao Q Phan; Deborah E Citrin; Nicholas P Restifo; Paul F Robbins; John R Wunderlich; Kathleen E Morton; Carolyn M Laurencot; Seth M Steinberg; Donald E White; Mark E Dudley
Journal:  Clin Cancer Res       Date:  2011-04-15       Impact factor: 12.531

3.  Mutant MHC class II epitopes drive therapeutic immune responses to cancer.

Authors:  Sebastian Kreiter; Mathias Vormehr; Niels van de Roemer; Mustafa Diken; Martin Löwer; Jan Diekmann; Sebastian Boegel; Barbara Schrörs; Fulvia Vascotto; John C Castle; Arbel D Tadmor; Stephen P Schoenberger; Christoph Huber; Özlem Türeci; Ugur Sahin
Journal:  Nature       Date:  2015-04-22       Impact factor: 49.962

4.  OX40 is a potent immune-stimulating target in late-stage cancer patients.

Authors:  Brendan D Curti; Magdalena Kovacsovics-Bankowski; Nicholas Morris; Edwin Walker; Lana Chisholm; Kevin Floyd; Joshua Walker; Iliana Gonzalez; Tanisha Meeuwsen; Bernard A Fox; Tarsem Moudgil; William Miller; Daniel Haley; Todd Coffey; Brenda Fisher; Laurie Delanty-Miller; Nicole Rymarchyk; Tracy Kelly; Todd Crocenzi; Eric Bernstein; Rachel Sanborn; Walter J Urba; Andrew D Weinberg
Journal:  Cancer Res       Date:  2013-10-31       Impact factor: 12.701

Review 5.  Adjuvants for enhancing the immunogenicity of whole tumor cell vaccines.

Authors:  Cheryl Lai-Lai Chiang; Lana E Kandalaft; George Coukos
Journal:  Int Rev Immunol       Date:  2011 Apr-Jun       Impact factor: 5.311

Review 6.  Combining immunotherapy and targeted therapies in cancer treatment.

Authors:  Matthew Vanneman; Glenn Dranoff
Journal:  Nat Rev Cancer       Date:  2012-03-22       Impact factor: 60.716

Review 7.  Current perspectives on immunotherapy.

Authors:  Jeffrey S Weber
Journal:  Semin Oncol       Date:  2014-09-08       Impact factor: 4.929

Review 8.  Cancer immunotherapy and breaking immune tolerance: new approaches to an old challenge.

Authors:  Amani Makkouk; George J Weiner
Journal:  Cancer Res       Date:  2014-12-18       Impact factor: 12.701

9.  Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer.

Authors:  Naiyer A Rizvi; Matthew D Hellmann; Alexandra Snyder; Pia Kvistborg; Vladimir Makarov; Jonathan J Havel; William Lee; Jianda Yuan; Phillip Wong; Teresa S Ho; Martin L Miller; Natasha Rekhtman; Andre L Moreira; Fawzia Ibrahim; Cameron Bruggeman; Billel Gasmi; Roberta Zappasodi; Yuka Maeda; Chris Sander; Edward B Garon; Taha Merghoub; Jedd D Wolchok; Ton N Schumacher; Timothy A Chan
Journal:  Science       Date:  2015-03-12       Impact factor: 47.728

10.  Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study.

Authors:  S L Topalian; D Solomon; F P Avis; A E Chang; D L Freerksen; W M Linehan; M T Lotze; C N Robertson; C A Seipp; P Simon
Journal:  J Clin Oncol       Date:  1988-05       Impact factor: 44.544

View more
  4 in total

Review 1.  [Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma].

Authors:  A Neubauer
Journal:  Internist (Berl)       Date:  2017-04       Impact factor: 0.743

Review 2.  Induced Pluripotent Stem Cell as a New Source for Cancer Immunotherapy.

Authors:  Farzaneh Rami; Halimeh Mollainezhad; Mansoor Salehi
Journal:  Genet Res Int       Date:  2016-02-25

Review 3.  Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis.

Authors:  Xiaohui Wang; Zhengqiang Bao; Xiaoju Zhang; Fei Li; Tianwen Lai; Chao Cao; Zhihua Chen; Wen Li; Huahao Shen; Songmin Ying
Journal:  Oncotarget       Date:  2017-05-31

4.  Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: A systematic review and meta-analysis.

Authors:  Rui Chen; Xiaoming Hou; Liping Yang; Da Zhao
Journal:  Thorac Cancer       Date:  2019-02-07       Impact factor: 3.500

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.